Segment, Customer and Geographical Reporting (Tables)

12 Months Ended

Sep. 30, 2019

The Company’s segment information is summarized below:


Results of Operations for the Fiscal Year Ended September 30,
2019
				Innovation and
				Development
				(formerly
				Contract
	Optics			Research)			Biomedical		Total
Revenue	$	23,250,000		$	20,451,000		$	—	$	43,701,000
Gross profit		7,939,000			8,135,000			—		16,074,000
GM %		34	%		40	%		—		37	%
Operating expenses		7,853,000			8,086,000			123,000		16,062,000
Impairment of long-lived assets		—			—			—		—
Operating income (loss)		86,000			49,000			(123,000)		12,000

Depreciation and amortization		1,165,000			241,000			14,000		1,420,000
Capital expenditures		716,000			177,000			—		893,000

Intangibles, net		307,000			128,000			192,000		627,000
Goodwill		882,000			4,939,000			—		5,821,000
Total assets	$	20,520,000		$	10,112,000		$	195,000	$	30,827,000


Results of Operations for the Fiscal Year Ended September 30,
2018
				Innovation and
	Optics			Development			Biomedical		Total
Revenue	$	23,053,000		$	17,628,000		$	—	$	40,681,000
Gross profit		7,667,000			7,569,000			—		15,236,000
GM %		33	%		43	%		—		37	%
Operating expenses		7,003,000			7,072,000			817,000		14,892,000
Impairment of long-lived assets		—			—			182,000		182,000
Operating income (loss)		664,000			497,000			(999,000)		162,000

Depreciation and amortization		1,006,000			237,000			14,000		1,257,000
Capital expenditures		2,033,000			211,000			73,000		2,317,000

Intangibles, net		390,000			162,000			203,000		755,000
Goodwill		961,000			4,939,000			—		5,900,000
Total assets	$	22,946,000		$	8,376,000		$	210,000	$	31,532,000

Revenue by geographic location in total and as a percentage of total revenue, for the years ended September 30, 2019 and 2018 are as follows: